ENDOGENOUS CIRCULATING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN MULTIPLE MYELOMA
To the Editor:
Previously, Zhang et al' suggested that granulocyte-macrophage colony-stimulating factor (GM-CSF) might be implicated in the pathogenesis of human multiple myeloma (MM). In a technically excellent work, they showed that GM-CSF is able to augment myeloma cell proliferation. Although GM-CSF alone has no proliferative activity on purified myeloma cells or myeloma cell lines, this stimulating activity on tumor cells is at least partially mediated by interleukin-6 (IL-6). This pleiotropic cytokine, originally described as a B-cell growth and differentiation factor, has evolved as the major growth factor for multiple myeloma cells.' However, the mechanism by which IL-6 triggers myeloma cell growth still remains controversial. Paracrine as well as autocrine mechanisms are under discu~sion?~ Recently, we demonstrated that in monoclonal gammopathies serum IL-6 levels correlate well with disease activity? We also found a correlation with serum neopterin, which is secreted by monocytes/macrophages upon stimulation with interferon-y (IFN-Y).~ These results implicate that circulating IL-6 might have its origin in an activated immune system rather than in the malignant cell clone.
In 35 patients with monoclonal gammopathies, serum samples were also screened for endogenous circulating GM-CSF using a commercially available enzyme-linked immunosorbent assay (ELISA; Medgenix, Brussels, Belgium). Twenty-six patients (pts) had an MM (14 pts with stage I disease, three with stage 11, and nine with stage 111) and nine presented with monoclonal gammopathy of unknown significance (MGUS). In contrast to the findings of Zhang et al,' significantly elevated levels of GM-CSF (> 25 pg/mL) were detected in 18 of 26 pts (69.2%) with MM and in 6 of 9 pts (66.6%) with MGUS. Median levels were 36 pg/mL (range, 0 to 183) in MM and 34 pg/mL (range, 10 to 63) in MGUS. GM-CSF levels correlated neither with disease stage nor with any of the other cytokines measured (IL-6, IL-lP, tumor necrosis factor-a [TNF-a], P 2-microglobulin, neopterin) or with absolute granulocyte counts. Nevertheless, GM-CSF might be of a certain pathogenetic significance in malignant plasma cell disorders, because in other hematologic malignancies such as chronic myeloproliferative diseases (n = 8) and low-grade non-Hodgkin's lymphomas of the B-cell type (n = 22), median values of GM-CSF were within the normal range (18 pg/mL, range, 0 to 80; and 19 pg/mL, range, 0 to 80, respectively). However, the source of circulating GM-CSF is still unknown. The findings of Zhang et all suggest that GM-CSF is not produced by the malignant clone itself. It is more likely that GM-CSF is secreted by cells of the immune system (monocytes/ macrophages or T lymphocytes) or accessory cells of the bone marrow upon stimulation by interleukins or IFNs, especially IFN-y. However, the lacking of correlation with neoptrein, an established parameter for activation of the host's cellular immune system,' makes it questionable whether a simple positive feedback mechanism exists for all these cytokines. It would also be interesting to investigate the kinetics of these cytokines during the natural course of disease and, probably more importantly, under chemotherapy, especially with biologicals such as IFN-a. 
